JP2008509147A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008509147A5 JP2008509147A5 JP2007524968A JP2007524968A JP2008509147A5 JP 2008509147 A5 JP2008509147 A5 JP 2008509147A5 JP 2007524968 A JP2007524968 A JP 2007524968A JP 2007524968 A JP2007524968 A JP 2007524968A JP 2008509147 A5 JP2008509147 A5 JP 2008509147A5
- Authority
- JP
- Japan
- Prior art keywords
- desmethylclozapine
- use according
- clozapine
- medicament
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JNNOSTQEZICQQP-UHFFFAOYSA-N Desmethylclozapine Chemical compound N=1C2=CC(Cl)=CC=C2NC2=CC=CC=C2C=1N1CCNCC1 JNNOSTQEZICQQP-UHFFFAOYSA-N 0.000 claims 25
- QZUDBNBUXVUHMW-UHFFFAOYSA-N Clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims 18
- 229960004170 clozapine Drugs 0.000 claims 18
- 239000003814 drug Substances 0.000 claims 18
- 102000014415 Muscarinic acetylcholine receptor family Human genes 0.000 claims 8
- 108050003473 Muscarinic acetylcholine receptor family Proteins 0.000 claims 8
- 206010061920 Psychotic disease Diseases 0.000 claims 5
- 229960004431 quetiapine Drugs 0.000 claims 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 3
- LNEPOXFFQSENCJ-UHFFFAOYSA-N Haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims 3
- KVWDHTXUZHCGIO-UHFFFAOYSA-N Olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 3
- MVWVFYHBGMAFLY-UHFFFAOYSA-N Ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims 3
- -1 etraphone Chemical compound 0.000 claims 3
- 201000008895 mood disease Diseases 0.000 claims 3
- 229960000607 ziprasidone Drugs 0.000 claims 3
- OHFQSNUBVNIZRV-UHFFFAOYSA-N 1-(4-phenylbutyl)piperazine Chemical compound C1CNCCN1CCCCC1=CC=CC=C1 OHFQSNUBVNIZRV-UHFFFAOYSA-N 0.000 claims 2
- 206010001443 Affective disease Diseases 0.000 claims 2
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims 2
- 206010057668 Cognitive disease Diseases 0.000 claims 2
- 229940003380 Geodon Drugs 0.000 claims 2
- 229940095895 Haldol Drugs 0.000 claims 2
- WJFKNYWRSNBZNX-UHFFFAOYSA-N Phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 claims 2
- 229950000688 Phenothiazine Drugs 0.000 claims 2
- WIKYUJGCLQQFNW-UHFFFAOYSA-N Prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 claims 2
- URKOMYMAXPYINW-UHFFFAOYSA-N Quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 2
- 229940035004 Seroquel Drugs 0.000 claims 2
- 229940076279 Serotonin Drugs 0.000 claims 2
- 229960004372 aripiprazole Drugs 0.000 claims 2
- 229910003002 lithium salt Inorganic materials 0.000 claims 2
- 159000000002 lithium salts Chemical class 0.000 claims 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 2
- 229960005017 olanzapine Drugs 0.000 claims 2
- ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 claims 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 2
- 229960003965 ANTIEPILEPTICS Drugs 0.000 claims 1
- 229940056213 Abilify Drugs 0.000 claims 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N Chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims 1
- 229960001076 Chlorpromazine Drugs 0.000 claims 1
- 229940068796 Clozaril Drugs 0.000 claims 1
- 229940088505 Compazine Drugs 0.000 claims 1
- 229960000394 Droperidol Drugs 0.000 claims 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N Droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 claims 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine dihydrochloride Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- XJGVXQDUIWGIRW-UHFFFAOYSA-N Loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 229960000300 Mesoridazine Drugs 0.000 claims 1
- SLVMESMUVMCQIY-UHFFFAOYSA-N Mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 claims 1
- 208000004296 Neuralgia Diseases 0.000 claims 1
- YVUQSNJEYSNKRX-UHFFFAOYSA-N Pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 claims 1
- 229960001534 Risperidone Drugs 0.000 claims 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N Risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 1
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 claims 1
- ZEWQUBUPAILYHI-UHFFFAOYSA-N Trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000003042 antagnostic Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000003556 anti-epileptic Effects 0.000 claims 1
- 230000000561 anti-psychotic Effects 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000003420 antiserotonin agent Substances 0.000 claims 1
- 230000003542 behavioural Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N dl-Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960003878 haloperidol Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical group [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims 1
- 229910052808 lithium carbonate Inorganic materials 0.000 claims 1
- 229960000423 loxapine Drugs 0.000 claims 1
- CRJHBCPQHRVYBS-UHFFFAOYSA-N mesoridazine besylate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 CRJHBCPQHRVYBS-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000000407 monoamine reuptake Effects 0.000 claims 1
- 239000003149 muscarinic antagonist Substances 0.000 claims 1
- 229960003634 pimozide Drugs 0.000 claims 1
- 229960003111 prochlorperazine Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 239000003723 serotonin 1A agonist Substances 0.000 claims 1
- 239000000952 serotonin receptor agonist Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 229960002784 thioridazine Drugs 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/913,117 US20050085463A1 (en) | 2003-01-23 | 2004-08-05 | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| US61755304P | 2004-10-08 | 2004-10-08 | |
| US11/098,892 US20050250767A1 (en) | 2003-01-23 | 2005-04-04 | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| PCT/US2005/027645 WO2006017614A1 (fr) | 2004-08-05 | 2005-08-04 | Utilisation de n-desmethylclozapine pour le traitement de maladie neuropsychiatrique humaine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008509147A JP2008509147A (ja) | 2008-03-27 |
| JP2008509147A5 true JP2008509147A5 (fr) | 2008-10-02 |
Family
ID=35511003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007524968A Pending JP2008509147A (ja) | 2004-08-05 | 2005-08-04 | ヒト神経精神病を治療するためのｎ−デスメチルクロザピンの使用 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1778244A1 (fr) |
| JP (1) | JP2008509147A (fr) |
| AU (1) | AU2005271513A1 (fr) |
| CA (1) | CA2576153A1 (fr) |
| WO (1) | WO2006017614A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2023909T3 (pl) * | 2006-05-04 | 2010-04-30 | Solvay Pharm Bv | Agonisty muskarynowe do leczenia zaburzeń kontroli impulsów |
| US8748419B2 (en) | 2006-06-16 | 2014-06-10 | Theracos, Inc. | Treating obesity with muscarinic receptor M1 antagonists |
| US7893053B2 (en) | 2006-06-16 | 2011-02-22 | Theracos, Inc. | Treating psychological conditions using muscarinic receptor M1 antagonists |
| GB0701970D0 (en) * | 2007-02-01 | 2007-03-14 | Wilson Stuart | Treatment of protein aggregation diseases |
| GB0708186D0 (en) * | 2007-04-27 | 2007-06-06 | Merck Sharp & Dohme | Therapeutic compounds |
| US9018202B2 (en) * | 2010-12-03 | 2015-04-28 | Allergan, Inc. | Methods for treating diseases of the retina |
| CN106749219A (zh) * | 2015-11-20 | 2017-05-31 | 江苏恩华药业股份有限公司 | 一种内酰胺类衍生物及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006515628A (ja) * | 2003-01-23 | 2006-06-01 | アカディア ファーマシューティカルズ，インコーポレーテッド | ヒト神経精神疾患を処置するためのｎ−デスメチルクロザピンの使用 |
| WO2004073639A2 (fr) * | 2003-02-19 | 2004-09-02 | Merck & Co. Inc. | Traitement de la psychose avec un activateur ectopique du recepteur m1 muscarinique |
-
2005
- 2005-08-04 EP EP05802835A patent/EP1778244A1/fr not_active Withdrawn
- 2005-08-04 WO PCT/US2005/027645 patent/WO2006017614A1/fr active Application Filing
- 2005-08-04 JP JP2007524968A patent/JP2008509147A/ja active Pending
- 2005-08-04 CA CA002576153A patent/CA2576153A1/fr not_active Abandoned
- 2005-08-04 AU AU2005271513A patent/AU2005271513A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8138169B2 (en) | Combination therapy for bipolar disorder | |
| JP5241228B2 (ja) | 非ステロイド性抗炎症薬、鬱血除去薬および鎮静作用の少ない抗ヒスタミン薬を含む多層錠 | |
| JP2006515628A5 (fr) | ||
| RU2005126614A (ru) | Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей | |
| US20060039866A1 (en) | Method for treating sleep-related breathing disorders | |
| US20080081804A1 (en) | Combination of Sabcomeline with a Neuroleptic Agent to Treat Psychotic Disorders | |
| JP2008509147A5 (fr) | ||
| TWI426906B (zh) | 治療精神分裂症的醫藥組成物 | |
| JP2010530422A (ja) | うつ病のための組合せ治療 | |
| JP2006528676A (ja) | 非定形型抗精神病薬と、ｇａｂａ調節薬及び／又は抗痙攣薬の治療上の組合せ | |
| JP2009525343A5 (fr) | ||
| CN101132777A (zh) | 用于睡眠障碍的药物组合物 | |
| AU2007319471A2 (en) | Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer | |
| BRPI0618239A2 (pt) | uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusico | |
| JP2016520653A5 (fr) | ||
| RU2011146032A (ru) | Соединения-агонисты рецептора 5-ht4 для лечения расстройств познавательной способности | |
| US20080306043A1 (en) | Sabcomeline Alone or Combined with a Mood Stabilising or Antimanic Agent to Treat Bipolar Disorders | |
| Leo et al. | Atypical antipsychotic use in the treatment of psychosis in primary care | |
| CN101119715A (zh) | 用于辅助性治疗精神分裂症的spm927 | |
| US20090035370A1 (en) | Dosage form and method of use | |
| US20220370454A1 (en) | Methods for treating central nervous system disorders with muscarinic receptor activation and antipsychotics | |
| CN117177741A (zh) | 用于治疗睡眠呼吸暂停的去甲肾上腺素再摄取抑制剂和大麻素的组合 | |
| JP2009501205A (ja) | 精神病治療用組成物 | |
| CN114585354A (zh) | 用芬氟拉明治疗癫痫患者的方法 | |
| WO2016027259A1 (fr) | Compositions pharmaceutiques pour le système nerveux central et procédés d'utilisation |